These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16638874)

  • 21. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
    J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
    Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
    Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
    Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
    Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
    Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy targets the mTOR signaling network in vitro and in vivo.
    Weyergang A; Berg K; Kaalhus O; Peng Q; Selbo PK
    Mol Pharm; 2009; 6(1):255-64. PubMed ID: 19125612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
    Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
    Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
    Zeng Q; Yang Z; Gao YJ; Yuan H; Cui K; Shi Y; Wang H; Huang X; Wong ST; Wang Y; Kesari S; Ji RR; Xu X
    Eur J Cancer; 2010 Apr; 46(6):1132-43. PubMed ID: 20156674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer.
    Fechner G; Classen K; Schmidt D; Hauser S; Müller SC
    Urology; 2009 Mar; 73(3):665-8; discussion 668-9. PubMed ID: 19081609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ.
    Fleming NI; Trivett MK; George J; Slavin JL; Murray WK; Moseley JM; Anderson RL; Thomas DM
    Cancer Res; 2009 Sep; 69(18):7473-9. PubMed ID: 19723659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
    Marimpietri D; Brignole C; Nico B; Pastorino F; Pezzolo A; Piccardi F; Cilli M; Di Paolo D; Pagnan G; Longo L; Perri P; Ribatti D; Ponzoni M
    Clin Cancer Res; 2007 Jul; 13(13):3977-88. PubMed ID: 17606732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.
    Martinez JM; Sali T; Okazaki R; Anna C; Hollingshead M; Hose C; Monks A; Walker NJ; Baek SJ; Eling TE
    J Pharmacol Exp Ther; 2006 Aug; 318(2):899-906. PubMed ID: 16714403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of mammary lesions represent molecular differences.
    Namba R; Maglione JE; Davis RR; Baron CA; Liu S; Carmack CE; Young LJ; Borowsky AD; Cardiff RD; Gregg JP
    BMC Cancer; 2006 Dec; 6():275. PubMed ID: 17147824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.